1. Home
  2. BTAI vs VSA Comparison

BTAI vs VSA Comparison

Compare BTAI & VSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BTAI
  • VSA
  • Stock Information
  • Founded
  • BTAI 2017
  • VSA 2002
  • Country
  • BTAI United States
  • VSA China
  • Employees
  • BTAI N/A
  • VSA N/A
  • Industry
  • BTAI Biotechnology: Pharmaceutical Preparations
  • VSA
  • Sector
  • BTAI Health Care
  • VSA
  • Exchange
  • BTAI Nasdaq
  • VSA NYSE
  • Market Cap
  • BTAI 8.3M
  • VSA 7.9M
  • IPO Year
  • BTAI 2018
  • VSA N/A
  • Fundamental
  • Price
  • BTAI $1.86
  • VSA $1.03
  • Analyst Decision
  • BTAI Buy
  • VSA
  • Analyst Count
  • BTAI 5
  • VSA 0
  • Target Price
  • BTAI $34.60
  • VSA N/A
  • AVG Volume (30 Days)
  • BTAI 295.5K
  • VSA 200.2K
  • Earning Date
  • BTAI 08-05-2025
  • VSA 08-21-2025
  • Dividend Yield
  • BTAI N/A
  • VSA N/A
  • EPS Growth
  • BTAI N/A
  • VSA N/A
  • EPS
  • BTAI N/A
  • VSA N/A
  • Revenue
  • BTAI $1,852,000.00
  • VSA $160,411,283.00
  • Revenue This Year
  • BTAI $5.03
  • VSA N/A
  • Revenue Next Year
  • BTAI $291.01
  • VSA N/A
  • P/E Ratio
  • BTAI N/A
  • VSA N/A
  • Revenue Growth
  • BTAI 5.47
  • VSA N/A
  • 52 Week Low
  • BTAI $1.17
  • VSA $0.18
  • 52 Week High
  • BTAI $21.92
  • VSA $2.00
  • Technical
  • Relative Strength Index (RSI)
  • BTAI 56.60
  • VSA N/A
  • Support Level
  • BTAI $1.69
  • VSA N/A
  • Resistance Level
  • BTAI $2.08
  • VSA N/A
  • Average True Range (ATR)
  • BTAI 0.21
  • VSA 0.00
  • MACD
  • BTAI 0.02
  • VSA 0.00
  • Stochastic Oscillator
  • BTAI 57.89
  • VSA 0.00

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

About VSA TCTM KIDS IT EDUCATION INC SPON ADS EA REP 5 ORD SHS(POST REV SPLT)

TCTM Kids IT Education Inc engages in the provision of IT-focused education services in Mainland China. The company has two operating segments: the IT Professional Education segment and the IT-focused Supplementary STEM Education Services segment. It offers supplementary science, technology, engineering, and mathematics (STEM) education programs to young children aged between three and eighteen through online teaching models and instructors from online or offline learning centers. The company also operates an education platform that offers distance instruction, classroom-based learning, and online learning modules.

Share on Social Networks: